BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 19436840)

  • 1. Romiplostim: a second-generation thrombopoietin agonist.
    Cohn CS; Bussel JB
    Drugs Today (Barc); 2009 Mar; 45(3):175-88. PubMed ID: 19436840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New drugs for familiar therapeutic targets: thrombopoietin receptor agonists and immune thrombocytopenic purpura.
    Kuter DJ
    Eur J Haematol Suppl; 2008 Feb; (69):9-18. PubMed ID: 18211568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombopoietin mimetic agents in the management of immune thrombocytopenic purpura.
    Newland A
    Semin Hematol; 2007 Oct; 44(4 Suppl 5):S35-45. PubMed ID: 18096471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New thrombopoietic growth factors.
    Kuter DJ
    Clin Lymphoma Myeloma; 2009; 9 Suppl 3():S347-56. PubMed ID: 19778863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New-generation drugs that stimulate platelet production in chronic immune thrombocytopenic purpura.
    Nurden AT; Viallard JF; Nurden P
    Lancet; 2009 May; 373(9674):1562-9. PubMed ID: 19324405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Romiplostim in chronic immune thrombocytopenic purpura.
    Cersosimo RJ
    Clin Ther; 2009 Sep; 31(9):1887-907. PubMed ID: 19843480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of chemotherapy-induced thrombocytopenia: current status of thrombopoietic agents.
    Vadhan-Raj S
    Semin Hematol; 2009 Jan; 46(1 Suppl 2):S26-32. PubMed ID: 19245931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic immune thrombocytopenic purpura. New agents.
    Rodeghiero F; Ruggeri M
    Hamostaseologie; 2009 Jan; 29(1):76-9. PubMed ID: 19151853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombopoietin and thrombopoietin mimetics in the treatment of thrombocytopenia.
    Kuter DJ
    Annu Rev Med; 2009; 60():193-206. PubMed ID: 19642221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of AMG-531 in the treatment of thrombocytopenia in idiopathic thrombocytopenic purpura and myelodysplastic syndromes.
    Tiu RV; Sekeres MA
    Expert Opin Biol Ther; 2008 Jul; 8(7):1021-30. PubMed ID: 18549331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The biology of thrombopoietin and thrombopoietin receptor agonists.
    Kuter DJ
    Int J Hematol; 2013 Jul; 98(1):10-23. PubMed ID: 23821332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Milestones in understanding platelet production: a historical overview.
    Kuter DJ
    Br J Haematol; 2014 Apr; 165(2):248-58. PubMed ID: 24528208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AMG 531: an investigational thrombopoiesis-stimulating peptibody.
    Nichol JL
    Pediatr Blood Cancer; 2006 Oct; 47(5 Suppl):723-5. PubMed ID: 16933266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Romiplostim: a novel thrombopoiesis-stimulating agent.
    Perreault S; Burzynski J
    Am J Health Syst Pharm; 2009 May; 66(9):817-24. PubMed ID: 19386944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of romiplostim for the treatment of patients with chronic immune thrombocytopenia: from bench to bedside.
    Molineux G; Newland A
    Br J Haematol; 2010 Jul; 150(1):9-20. PubMed ID: 20298251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of immunogenicity of romiplostim in clinical studies with ITP subjects.
    Jawa V; Hokom M; Hu Z; El-Abaadi N; Zhuang Y; Berger D; Gupta S; Swanson SJ; Chirmule N
    Ann Hematol; 2010 Jul; 89 Suppl 1(Suppl 1):75-85. PubMed ID: 20155267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New insights and therapeutics for immune-mediated thrombocytopenia.
    Metjian A; Abrams CS
    Expert Rev Cardiovasc Ther; 2008 Jan; 6(1):71-84. PubMed ID: 18095908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New thrombopoietic growth factors.
    Kuter DJ
    Blood; 2007 Jun; 109(11):4607-16. PubMed ID: 17289815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations.
    Aoki T; Harada Y; Matsubara E; Suzuki T; Oyama T; Kasai M; Uchida T; Ogura M
    J Clin Pharm Ther; 2012 Dec; 37(6):729-32. PubMed ID: 22583038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): a "real life" retrospective multicenter experience of the Rete Ematologica Pugliese (REP).
    Mazza P; Minoia C; Melpignano A; Polimeno G; Cascavilla N; Di Renzo N; Specchia G
    Ann Hematol; 2016 Jan; 95(2):239-44. PubMed ID: 26596973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.